ATE457988T1 - A2a-adenosin-rezeptor-antagonisten - Google Patents

A2a-adenosin-rezeptor-antagonisten

Info

Publication number
ATE457988T1
ATE457988T1 AT07796492T AT07796492T ATE457988T1 AT E457988 T1 ATE457988 T1 AT E457988T1 AT 07796492 T AT07796492 T AT 07796492T AT 07796492 T AT07796492 T AT 07796492T AT E457988 T1 ATE457988 T1 AT E457988T1
Authority
AT
Austria
Prior art keywords
receptor antagonists
adenosine receptor
alkyl
compounds
cns diseases
Prior art date
Application number
AT07796492T
Other languages
English (en)
Inventor
Martin C Clasby
Samuel Chackalamannil
Andrew Stamford
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE457988T1 publication Critical patent/ATE457988T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT07796492T 2006-06-26 2007-06-25 A2a-adenosin-rezeptor-antagonisten ATE457988T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81651606P 2006-06-26 2006-06-26
PCT/US2007/014886 WO2008002596A2 (en) 2006-06-26 2007-06-25 Adenosine a2a receptor antagonists

Publications (1)

Publication Number Publication Date
ATE457988T1 true ATE457988T1 (de) 2010-03-15

Family

ID=38846284

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07796492T ATE457988T1 (de) 2006-06-26 2007-06-25 A2a-adenosin-rezeptor-antagonisten

Country Status (10)

Country Link
US (1) US7713985B2 (de)
EP (1) EP2038285B1 (de)
JP (1) JP2010509189A (de)
CN (1) CN101506215A (de)
AT (1) ATE457988T1 (de)
CA (1) CA2655987A1 (de)
DE (1) DE602007004851D1 (de)
ES (1) ES2339502T3 (de)
MX (1) MX2009000104A (de)
WO (1) WO2008002596A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011513417A (ja) 2008-03-04 2011-04-28 シェーリング コーポレイション アデノシンＡ２ａ受容体アンタゴニストとして使用するための１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オンおよびピラゾロ［４，３−ｅ］−１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オン化合物
WO2009136578A1 (ja) * 2008-05-09 2009-11-12 パイオニア株式会社 空間映像表示装置
AU2010222289B2 (en) 2009-03-13 2013-07-11 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds
TWI548411B (zh) 2009-04-28 2016-09-11 Kyowa Hakko Kirin Co Ltd Exercise disorder treatment
EP2509983B1 (de) 2009-11-16 2014-09-17 Merck Sharp & Dohme Corp. Kondensierte tricyclische verbindungen mit adenosin-a2a-rezeptorantagonistenwirkung
WO2011101861A1 (en) 2010-01-29 2011-08-25 Msn Laboratories Limited Process for preparation of dpp-iv inhibitors
AU2011306358B2 (en) * 2010-09-24 2014-08-14 Impetis Biosciences Ltd. Fused tricyclic compounds as adenosine receptor antagonist
KR20140146217A (ko) * 2012-04-20 2014-12-24 유씨비 파마, 에스.에이. 파킨슨병을 치료하는 방법
CN102659620A (zh) * 2012-05-18 2012-09-12 东南大学 2,4-双(三氟甲基)苄肼的合成方法
WO2014101113A1 (en) * 2012-12-28 2014-07-03 Merck Sharp & Dohme Corp. Piperazine-substituted 7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
CN105025899B (zh) * 2012-12-28 2017-08-18 默沙东公司 具有A2A拮抗剂性质的杂二环取代的‑[1,2,4]三唑并[1,5‑c]喹唑啉‑5‑胺化合物
WO2014101120A1 (en) 2012-12-28 2014-07-03 Merck Sharp & Dohme Corp. Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
US12414952B2 (en) 2018-11-20 2025-09-16 Merck Sharp & Dohme Llc Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
AU2019383948A1 (en) 2018-11-20 2021-05-20 Merck Sharp & Dohme Llc Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
WO2020112700A1 (en) 2018-11-30 2020-06-04 Merck Sharp & Dohme Corp. 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use
AU2019388872A1 (en) 2018-11-30 2021-05-27 Merck Sharp & Dohme Llc 7-, 8-, and 10-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use
US12398139B2 (en) 2019-03-05 2025-08-26 Centre For Addiction And Mental Health Modulators of AMPA receptor signaling
CA3177056A1 (en) 2020-03-26 2021-09-30 Astrazeneca Ab 5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancer
KR20230049580A (ko) 2020-03-26 2023-04-13 헵테얼즈 테라퓨틱스 리미티드 트리아졸론 화합물
WO2021191376A1 (en) 2020-03-26 2021-09-30 Astrazeneca Ab Triazolone compounds
WO2021191378A1 (en) 2020-03-26 2021-09-30 Astrazeneca Ab 5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955465A (en) * 1996-03-22 1999-09-21 Neurogen Corporation 1,2,4-triazolo 4,3-c!quinazolin-3-ones and 1,2,4-triazolo 4,3-c!quinazolin-3-thiones
AU2003291608A1 (en) * 2002-12-27 2004-07-22 Actar Ab A method of drug screening to select agonists or antagonists of g protein coupled receptors (gpcr).
US7452892B2 (en) * 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
EP1934227B1 (de) * 2005-09-19 2011-12-21 Schering Corporation 2-HETEROARYLPYRAZOLO[4,3-e]-1, 2, 4-TRIAZOLO-[1,5-c]-PYRIMIDINE ALS ANTAGONISTEN DES ADENOSIN-A2a-REZEPTORS

Also Published As

Publication number Publication date
CA2655987A1 (en) 2008-01-03
ES2339502T3 (es) 2010-05-20
MX2009000104A (es) 2009-01-23
WO2008002596A3 (en) 2008-07-03
JP2010509189A (ja) 2010-03-25
US20080255156A1 (en) 2008-10-16
CN101506215A (zh) 2009-08-12
WO2008002596A2 (en) 2008-01-03
DE602007004851D1 (de) 2010-04-01
EP2038285B1 (de) 2010-02-17
EP2038285A2 (de) 2009-03-25
US7713985B2 (en) 2010-05-11

Similar Documents

Publication Publication Date Title
ATE457988T1 (de) A2a-adenosin-rezeptor-antagonisten
TW200726765A (en) Triazolopyridine cannabinoid receptor 1 antagonists
TNSN07164A1 (en) Quinuclidine derivatives and their use as muscarinic m3 receptor antagonists
MX340965B (es) Combinaciones para el tratamiento de enfermedades que involucran la proliferacion celular.
GEP20115174B (en) Triazolopyrazine derivatives useful as anti-cancer agents
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
PL1697371T3 (pl) Azabicykliczne heterocykle jako modulatory receptora kanabinoidowego
PH12012501122A1 (en) Pteridinones as inhibitors of polo-like kinase
NO20084853L (no) Forbindelser som er agonister av muscarinreseptorer og som kan vaere effektive i behandling av smerte, Alzheimers sykdom og/eller schizofreni
MX2012004848A (es) Compuestos heterociclicos triciclicos.
MX2009009238A (es) Nuevos inhibidores de fosfodiesterasa.
PL1891029T3 (pl) Związki organiczne do leczenia stanów zapalnych lub alergicznych
UA92670C2 (ru) Пиразолиновые соединения и их фармацевтическое применение, композиция на их основе
MX2010001020A (es) Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas.
MY169274A (en) Fused, tricyclic sulfonamide inhibitors of gamma secretase
MX2010002938A (es) Derivados de (3-hidroxi-4-amino-butan-2-il)-3-(2-tiazol-2-il-pirro lidin-1-carbonil)benzamida y compuestos relacionados como inhibidores de beta-secretasa para tratar enfermedad de alzheimer.
MX2009011059A (es) Aminopirimidinas utiles como inhibidores de cinasas.
MA28706B1 (fr) Antagoniste des recepteurs du glucagon, preparation et utilisations therapeutiques
DE602007001463D1 (de) Pyrimidin-, chinazolin-, pteridin- und triazinderivate
TW200637863A (en) Organic compounds
ATE446089T1 (de) 2-benzoyl-imidazopyridin-derivate, herstellungsverfahren und ihre verwendung für therapeutika
MX2007013624A (es) Inhibidores de proteina cinasa.
TW200716547A (en) Piperidin-4-yl-amide derivatives
TW200630366A (en) Organic compounds
TW200639156A (en) New compounds

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties